Clearmind Medicine (NASDAQ:CMND) Releases Quarterly Earnings Results

Clearmind Medicine (NASDAQ:CMND) released its quarterly earnings results on Thursday. The company reported ($0.57) earnings per share for the quarter, FiscalAI reports.

Clearmind Medicine Price Performance

CMND stock opened at $0.98 on Friday. The company’s 50 day simple moving average is $1.73 and its 200-day simple moving average is $4.93. Clearmind Medicine has a 12 month low of $0.92 and a 12 month high of $524.00. The firm has a market capitalization of $999,600.00, a PE ratio of -0.01 and a beta of 0.81.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised Clearmind Medicine from a “strong sell” rating to a “sell” rating in a report on Saturday, June 20th.

Insider Activity

In related news, major shareholder Financial Lp Hrt sold 22,139 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $3.31, for a total value of $73,280.09. Following the sale, the insider owned 81,353 shares of the company’s stock, valued at approximately $269,278.43. This represents a 21.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Clearmind Medicine Company Profile

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.